(Q38118388)

29 August 2017

title

Targeting tyrosine-kinases in ovarian cancer (English)

1 reference

29 August 2017

1 reference

4

Simone Ferrero

1 reference

29 August 2017

Matteo Morotti

1

1 reference

29 August 2017

Christian M Becker

series ordinal

2

1 reference

29 August 2017

Mario Valenzano Menada

series ordinal

3

1 reference

29 August 2017

language of work or name

English

0 references

publication date

2 July 2013

1 reference

Expert Opinion on Investigational Drugs

29 August 2017

published in

1 reference

29 August 2017

volume

22

1 reference

29 August 2017

issue

10

1 reference

29 August 2017

page(s)

1265-1279

1 reference

29 August 2017

cites work

Cancer statistics, 2012

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

Recent progress in the diagnosis and treatment of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

Novel agents on the horizon for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

Perspective: Dynamics of receptor tyrosine kinase signaling complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

Regulation and targets of receptor tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

Tyrosine kinase inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

Epidermal growth factor receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

The protein kinase complement of the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

Targeting angiogenesis in ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

Role of tyrosine kinase inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

Angiogenesis as a therapeutic target

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

PDGF and vessel maturation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

Angiogenesis and ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

Targeted anti-vascular therapies for ovarian cancer: current evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

Significance of vascular endothelial growth factor in growth and peritoneal dissemination of ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

Vascular endothelial growth factor and interleukin-8 are associated with poor prognosis in epithelial ovarian cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

Expression of platelet-derived growth factor and activated receptor in clinical specimens of epithelial ovarian cancer and ovarian carcinoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

Immunohistochemical expression of platelet-derived growth factor receptors in ovarian cancer patients with long-term follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

Epidermal growth factor receptor signaling and the invasive phenotype of ovarian carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

Immunohistochemical expression of epidermal growth factor receptor, E-cadherin, and matrix metalloproteinase-9 in ovarian epithelial cancer and relation to patient deaths

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

Sorafenib in Combination With Gemcitabine in Recurrent Epithelial Ovarian Cancer: A Study of the Princess Margaret Hospital Phase II Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

Sorafenib in combination with weekly topotecan in recurrent ovarian cancer, a phase I/II study of the Hoosier Oncology Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

Sorafenib in combination with carboplatin and paclitaxel as neoadjuvant chemotherapy in patients with advanced ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

Combination targeted therapy with sorafenib and bevacizumab results in enhanced toxicity and antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor mo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

The PACOVAR-trial: a phase I/II study of pazopanib (GW786034) and cyclophosphamide in patients with platinum-resistant recurrent, pre-treated ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

Dual-agent molecular targeting of the ErbB2 receptor: killing one bird with two stones

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

Initial toxicity assessment of ICON6: a randomised trial of cediranib plus chemotherapy in platinum-sensitive relapsed ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

Untangling the ErbB signalling network

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

Erlotinib added to carboplatin and paclitaxel as first-line treatment of ovarian cancer: a phase II study based on surgical reassessment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

A phase Ib trial of docetaxel, carboplatin and erlotinib in ovarian, fallopian tube and primary peritoneal cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

A phase II study of erlotinib (OSI-774) given in combination with carboplatin in patients with recurrent epithelial ovarian cancer (NCIC CTG IND.149).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

Phase II study of gefitinib in combination with paclitaxel (P) and carboplatin (C) as second-line therapy for ovarian, tubal or peritoneal adenocarcinoma (1839IL/0074).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

A phase I study of lapatinib in combination with carboplatin in women with platinum sensitive recurrent ovarian carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

Phase II trial of lapatinib and topotecan (LapTop) in patients with platinum-refractory/resistant ovarian and primary peritoneal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

A phase II evaluation of lapatinib in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a gynecologic oncology group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

Multicenter, randomized phase II trial of oral CI-1033 for previously treated advanced ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis : a Hoosier Oncology Group trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

Phase II evaluation of imatinib mesylate in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

A phase I trial of dasatinib, an SRC-family kinase inhibitor, in combination with paclitaxel and carboplatin in patients with advanced or recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

Phase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

Predictive and prognostic angiogenic markers in a gynecologic oncology group phase II trial of bevacizumab in recurrent and persistent ovarian or peritoneal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

Molecular Biomarkers of Response to Antiangiogenic Therapy for Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

Biomarkers in the development of anti-angiogenic therapies for ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

EGFR gene copy number as a prognostic marker in colorectal cancer patients treated with cetuximab or panitumumab: a systematic review and meta analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

Adjuvant therapy of gastrointestinal stromal tumors (GIST).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

Pushing the limits of targeted therapy in chronic myeloid leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

Taming the dragon: genomic biomarkers to individualize the treatment of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

Clinical pharmacokinetics of tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

Mechanisms of drug resistance in kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

Cancer incidence and mortality in Europe, 2004

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2013.816282

10.1517/13543784.2013.816282

21 January 2018

Identifiers

DOI

1 reference

29 August 2017

1 reference